Orexo AB (ORXOF) Price & Analysis

8 Followers

ORXOF Stock Chart & Stats

$1.42

-$0.33(-15.71%)

At close: Jul 16 4:00 PM EDT

$1.42

-$0.33(-15.71%)

Day’s Range― - ―

52-Week Range$1.28 - $4.09

Previous CloseN/A

Volume5.88K

Average Volume (3M)66.00

Market Cap

$48.64M

Enterprise Value$576.03

Total Cash (Recent Filing)$276.90M

Total Debt (Recent Filing)$9.90M

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Oct 22, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-8.81

Shares Outstanding35,127,056

10 Day Avg. Volume0

30 Day Avg. Volume66

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)2.12

Price to Sales (P/S)40.09

P/FCF Ratio6.02

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.94

Revenue Forecast (FY)$2.70M

Bulls Say, Bears Say

Bulls Say

Long-lived IP And PipelineLong patent runways can protect future products from direct competition and support partnering or licensing value. OX640, GLP-1 and other AmorphOX programs provide multiple potential growth avenues beyond Orexo’s legacy products.

Pipeline And Funding ProgressPositive preclinical progress and external BARDA financing reduce Orexo’s direct funding burden for OX390 while advancing a potential new product. Continued development progress can diversify the portfolio and improve strategic partnering prospects.

Improved Leverage And Cost BaseLower leverage provides more financial flexibility than in prior periods, while the normalized cost base indicates savings after one-off expenses and transition costs. Together, these factors could improve resilience if product revenue and partnerships recover.

Bears Say

Severe Profitability And Revenue PressureThe core business is currently not covering its cost base, and the sharp revenue decline weakens operating leverage. Persistent losses could limit investment capacity and make Orexo increasingly dependent on successful launches, licensing or external financing.

Cash Burn And Uncertain DurabilityRecent cash generation has not been sustained: a large quarterly outflow materially reduced available liquidity despite reported cash reserves. Continued development spending, legal costs and low revenue could accelerate funding needs before new products contribute.

DOJ And Financing UncertaintyAn unresolved investigation creates potentially material legal liabilities and ongoing advisory costs while complicating capital planning. Until the outcome is known, financing flexibility may remain limited and partners or investors may require greater risk compensation.

Orexo AB News

Orexo AB Earnings Call: Science Progress, Cash Strain

Orexo AB (($SE:ORX)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

Orexo Advances Nasal Rescue Pipeline as Losses Deepen in Q2 2026

An update from Orexo AB ( ($SE:ORX) ) is now available. Orexo reported second-quarter 2026 net revenues of...

1M ago

Orexo strengthens partnership strategy with new business development chief

Orexo AB ( ($SE:ORX) ) has provided an announcement. Orexo has bolstered its leadership team by appointing biopharma...

3M ago

Orexo posts positive in‑vivo data for nasal overdose reversal candidate OX390

Orexo AB ( ($SE:ORX) ) has shared an announcement. Orexo has reported positive pre‑clinical in‑vivo data for OX390,...

3M ago

Orexo AGM Backs Board, Expands Capital Flexibility and Incentive Plans

Orexo AB ( ($SE:ORX) ) has shared an update. Orexo’s annual general meeting re-elected its five-member board, confirmed...

4M ago

Orexo Deepens R&D Push as Losses Widen and Bond Redeemed Early

Orexo AB ( ($SE:ORX) ) has provided an announcement. Orexo reported weak first-quarter 2026 financials from its continued...

4M ago

Orexo updates share and voting structure after class C conversion

The latest announcement is out from Orexo AB ( ($SE:ORX) ). Orexo AB has reported its updated share...

5M ago

Orexo Calls 2026 AGM to Decide on Governance, Capital Measures and Incentive Plan

Orexo AB ( ($SE:ORX) ) has provided an update. Orexo AB has called its shareholders to an annual...

5M ago

Orexo Publishes 2025 Annual and Sustainability Reports Detailing Strategy and Market Position

Orexo AB ( ($SE:ORX) ) has provided an announcement. Orexo AB has published its Annual Report 2025, outlining...

5M ago

Orexo Restructures Leadership to Drive Pipeline and AmorphOX-Focused Growth

The latest update is out from Orexo AB ( ($SE:ORX) ). Orexo AB is reshaping its organization and...

6M ago

ORXOF FAQ

What was Orexo AB’s price range in the past 12 months?

Orexo AB lowest stock price was $1.28 and its highest was $4.09 in the past 12 months.

What is Orexo AB’s market cap?

Orexo AB’s market cap is $48.64M.

When is Orexo AB’s upcoming earnings report date?

Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 55 days.

How were Orexo AB’s earnings last quarter?

Orexo AB released its earnings results on Jul 16, 2026. The company reported -$0.228 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.062.

Is Orexo AB overvalued?

According to Wall Street analysts Orexo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orexo AB pay dividends?

Orexo AB does not currently pay dividends.

What is Orexo AB’s EPS estimate?

Orexo AB’s EPS estimate is -0.22.

How many shares outstanding does Orexo AB have?

Orexo AB has 35,127,056 shares outstanding.

What happened to Orexo AB’s price movement after its last earnings report?

Orexo AB reported an EPS of -$0.228 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -23.043%.

Which hedge fund is a major shareholder of Orexo AB?

Currently, no hedge funds are holding shares in ORXOF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Orexo AB (ORXOF) Earnings & Revenues

Historic Earnings Reports

ORXOF Company Deck

ORXOF Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all ORXOF earnings summaries